ARA-290

ARA-290 Immunological Pathway Overview

ARA-290 is profoundly integrated into the fundamental regulation of systemic defense, providing immense therapeutic capacity for cellular pathogen neutralization and immune cell differentiation.

Physiochemical Diagnostics

Parameter	Value
Molecular Formula	C51H84N16O21
Molecular Mass	1257.3 g/mol
Assay Purity	>99.0%
Appearance	Lyophilized white cake

Figure 1: ARA-290 Action Within Defense Biology

Cytokine / T-Cell Cascade

The direct pathway fundamentally altering the deep cell defense environment:

1. Functions as an eleven-amino-acid synthetic analogue of Erythropoietin (EPO).
2. Engineered explicitly to separate neuroprotection from hematopoietic (red blood cell) creation.
3. Binds purely to the innate repair receptor (IRR) heterocomplex.
4. Triggers intense, localized suppression of inflammatory neuropathic pain signaling.
5. Promotes widespread physical nerve fiber re-myelination.

Figure 2: Empirical Rate of Pathogen Neutralization Output

Primary Clinical Outputs

• Vector 1: Revolutionized the research of small-fiber neuropathy reversal.
• Vector 2: Provides all the tissue-saving benefits of EPO without causing dangerous blood thickening (polycythemia).
• Vector 3: Frequently utilized in studying the rapid attenuation of severe mechanical nerve trauma.

Non-Hematopoietic EPO Signaling

ARA-290 is an 11-amino acid synthetic peptide derived from the three-dimensional structure of erythropoietin (EPO), specifically engineered to activate the innate repair receptor (IRR)—a heterodimer of the EPO receptor and the beta common receptor (CD131)—without stimulating classical erythropoiesis. This dissociation is critical: while EPO’s blood-forming effects cause dangerous polycythemia and thrombosis at therapeutic doses, ARA-290 delivers the tissue-protective and anti-inflammatory benefits of EPO signaling through a completely independent receptor complex.

1. ARA-290 selectively binds the IRR (EPOR/CD131 heterodimer) expressed on neurons, Schwann cells, endothelial cells, and macrophages.
2. IRR activation triggers JAK2/STAT5 and PI3K/Akt anti-apoptotic signaling cascades within target cells.
3. In macrophages, ARA-290 promotes a phenotypic switch from M1 (pro-inflammatory) to M2 (reparative), reducing TNF-α and IL-1β while increasing IL-10 and TGF-β.
4. In peripheral nerves, the peptide activates Schwann cell proliferation and remyelination programs, restoring nerve conduction velocity in neuropathy models.
5. Unlike EPO, ARA-290 does not bind the classical homodimeric EPOR, producing no effect on red blood cell production, hematocrit, or platelet count.

Neuropathy & Inflammation Research

• Small Fiber Neuropathy: A Phase 2 clinical trial in sarcoidosis patients with small fiber neuropathy showed ARA-290 significantly improved corneal nerve fiber density (measured by confocal microscopy) and reduced neuropathic pain scores.
• Diabetic Neuropathy: Preclinical studies demonstrate ARA-290 restores intraepidermal nerve fiber density and normalizes nerve conduction velocity in streptozotocin-induced diabetic rodent models.
• Cardiac Protection: In myocardial ischemia-reperfusion models, ARA-290 reduces infarct size by 40–50% when administered at reperfusion, through inhibition of cardiomyocyte apoptosis.
• Chronic Kidney Disease: ARA-290 reduces tubulointerstitial fibrosis and inflammatory cell infiltration in 5/6 nephrectomy models without affecting erythropoiesis.
• Safety Profile: Human trials report ARA-290 as well-tolerated with no hematological effects, distinguishing it fundamentally from therapeutic EPO. Administered subcutaneously at doses of 2–8 mg.